Showing 201-210 of 9109 results for "".
- RXI Completes Enrollment of Phase 2 Study of Samcyprone for Cutaneous Wartshttps://practicaldermatology.com/news/rxi-completes-enrollment-of-phase-2-study-of-samcyprone-for-cutaneous-warts/2458067/RXi Pharmaceuticals Corporation completed enrollment in its Phase 2 clinical trial, RXI-SCP-1502, with Samcyprone™for the clearance of cutaneous warts. Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopropenone (DPCP). This topical immunomodulator works by initi…
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The BLA filing for tildrakizumab was submitted by Merck &…
- Positive Results Announced from SebuDerm Gel Study in Treatment of Seborrheic Dermatitishttps://practicaldermatology.com/news/positive-results-announced-from-sebuderm-gel-study-in-treatment-of-seborrheic-dermatitis/2458237/The results of a clinical study evaluating the impact of Sonoma Pharmaceuticals, Inc.'s SebuDerm (topical hypochlorous acid) gel in the treatment of mild to moderate facial and scalp seborrheic dermatitis were presented at the 13th Annual Maui Dermatology Conference in Maui, HI. In a 25-patient st…
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key secondary endpoints. There are no currently approved treatments for prurigo nodular…
- Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Linehttps://practicaldermatology.com/news/obagi-medical-products-collaborates-with-suzan-obagi-md-and-nextcell-medical-to-introduce-new-line/2458274/Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s line of skin care products throughout the United States. Established in 2013 with cosmetic surgeon and dermato…
- Oculus Innovative Sciences' SebuDerm Gel Availablehttps://practicaldermatology.com/news/fda-clears-oculus-innovative-sciences-sebuderm-gel/2458340/Oculus Innovative Sciences, Inc.’s Microcyn-based SebuDerm Gel is available in the US. As a prescription product, SebuDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. The gel, which was granted FDA 5…
- Paratek Initiates Phase 3 Study of Oral Omadacycline for MRSA, Acute Skin Infectionshttps://practicaldermatology.com/news/paratek-initiates-phase-3-study-of-oral-omadacycline-for-mrsa-acute-skin-infections/2458465/The first patient has been dosed in Paratek Pharmaceuticals, Inc.’s second pivotal Phase 3 study of omadacycline for acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiri…
- Melanoma Survival Rates Lower in Patients with Skin of Colorhttps://practicaldermatology.com/news/melanoma-survival-rates-lower-in-patients-with-skin-of-color/2458482/Although patients with skin of color are less likely to develop melanoma than caucasian patients, they have a higher rate of mortality from the disease, new research shows. Writing in the Jounral of the American Academy of Dermatology, Jeremy S. Bordeaux, MD, MPH, FAAD and colleagues reveal that Af…
- Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelengthhttps://practicaldermatology.com/news/syneron-candelas-picoway-picosecond-laser-receives-us-fda-clearance-for-ultra-short-785nm-wavelength/2458489/And then there were three. The U.S. Food and Drug Administration (FDA) has cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for a new ultra-short 785nm wavelength. The addition of the new wavelength expands the capabilities of the PicoWay picosecond laser, making it possible to remove all…
- Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Directorhttps://practicaldermatology.com/news/valeant-pharmaceuticals-appoints-thomas-w-ross-sr-lead-independent-director/2458532/Valeant Pharmaceuticals International, Inc.'s Board of Directors appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board's Nominating and Corporate Governance Committee and is Chairperson of its Con…